表紙
市場調查報告書

黑皮質素4受體:開發中產品分析

Melanocortin Receptor 4 - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 359406
出版日期 內容資訊 英文 80 Pages
訂單完成後即時交付
價格
Back to Top
黑皮質素4受體:開發中產品分析 Melanocortin Receptor 4 - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 80 Pages
簡介

本報告提供黑皮質素4受體的開發情形相關調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息與新聞稿等資訊。

簡介

  • 調查範圍

黑皮質素4受體概要

治療藥的開發

黑皮質素4受體:開發中的產品 - 各開發階段

黑皮質素4受體:開發中的產品 - 各治療範圍

黑皮質素4受體開發中的產品 - 各適應症

黑皮質素4受體:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

黑皮質素4受體:企業開發中的產品

黑皮質素4受體:大學/機關開發中的產品

黑皮質素4受體:治療藥的評估

  • 單劑產品
  • 各產品
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

黑皮質素4受體的治療藥開發企業

  • AstraZeneca Plc
  • Mallinckrodt Plc
  • Obexia AG
  • Palatin Technologies, Inc.
  • Pfizer Inc.
  • Retrophin Inc.
  • Rhythm Pharmaceuticals, Inc.

黑皮質素4受體:藥物簡介

黑皮質素4受體:暫停中的計劃

黑皮質素4受體:開發中止的產品

黑皮質素4受體:主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2029TDB

Summary

Melanocortin Receptor 4 (MC4R) pipeline Target constitutes close to 9 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The latest report Melanocortin Receptor 4 - Pipeline Review, H2 2019, outlays comprehensive information on the Melanocortin Receptor 4 (MC4R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Melanocortin Receptor 4 (MC4R) - Melanocortin 4 receptor (MC4R) is a G protein-coupled receptor involved in the hypothalamic leptin-melanocortin signaling pathway. MC4R is encoded by the MC4R gene. Activation of the MC4R plays a key role in the maintenance of energy homeostasis and is associated with suppression of food intake. The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 1 and 5 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Genetic Disorders, Musculoskeletal Disorders, Central Nervous System and Immunology which include indications Obesity, Type 2 Diabetes, Cachexia, Gouty Arthritis (Gout), Infantile Spasm (West Syndrome), Lipodystrophy (Lipoatrophy), Metabolic Syndrome, Multiple Sclerosis, Prader-Willi Syndrome (PWS), Rheumatoid Arthritis and Smith-Magenis Syndrome (Chromosome 17p11.2 Deletion Syndrome).

Furthermore, this report also reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Melanocortin Receptor 4 (MC4R)
  • The report reviews Melanocortin Receptor 4 (MC4R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Melanocortin Receptor 4 (MC4R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Melanocortin Receptor 4 (MC4R) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Melanocortin Receptor 4 (MC4R)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Melanocortin Receptor 4 (MC4R) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Melanocortin Receptor 4 (MC4R) - Overview
  • Melanocortin Receptor 4 (MC4R) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Melanocortin Receptor 4 (MC4R) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Melanocortin Receptor 4 (MC4R) - Companies Involved in Therapeutics Development
  • Aequus BioPharma Inc
  • Eton Pharmaceuticals Inc
  • Palatin Technologies Inc
  • Rhythm Pharmaceuticals Inc
  • Melanocortin Receptor 4 (MC4R) - Drug Profiles
  • (liraglutide + setmelanotide) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AQB-565 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • bremelanotide acetate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • corticotropin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • corticotropin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PL-8905 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PL-9610 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • setmelanotide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • setmelanotide ER - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize MC4-R for Obesity - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize Melanocortin-4 Receptor for Cachexia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Melanocortin Receptor 4 (MC4R) - Dormant Products
  • Melanocortin Receptor 4 (MC4R) - Discontinued Products
  • Melanocortin Receptor 4 (MC4R) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 16, 2019: First patient enrolled in Mallinckrodt phase 4 trial of Acthar Gel (Repository Corticotropin Injection) for Severe Keratitis
  • Dec 05, 2019: Rhythm Pharmaceuticals completes enrollment of pivotal cohort in phase 3 clinical trial evaluating Setmelanotide in Bardet-Biedl and Alstrom Syndromes
  • Nov 26, 2019: Data on Acthar Gel (Repository Corticotropin Injection) Therapy in Symptomatic Sarcoidosis published in Therapeutic Advances in Respiratory Disease
  • Nov 12, 2019: Mallinckrodt announces new clinical data evaluating Acthar Gel (Repository Corticotropin Injection) in Rheumatoid Arthritis (RA) at the 2019 American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) Annual Meeting
  • Nov 07, 2019: Mallinckrodt announces data Publication on the treatment Effectiveness of Acthar Gel (Repository Corticotropin Injection) for resolution of multiple sclerosis relapse in a U.S. Health Plan Population
  • Nov 04, 2019: Rhythm Pharmaceuticals announces late-breaking data from phase 3 trials of Setmelanotide in POMC and LEPR deficiency obesities at ObesityWeek 2019
  • Oct 30, 2019: Rhythm Pharmaceuticals announces late-breaking data presentations at ObesityWeek 2019
  • Oct 16, 2019: Vyleesi phase 3 data to be presented at the 13th European Society Of Gynecology Congress
  • Oct 01, 2019: Mallinckrodt announces positive top-line findings from its observational registry assessing relapse recovery in multiple sclerosis relapse patients treated with Acthar Gel (Repository Corticotropin Injection)
  • Sep 25, 2019: Rhythm Pharmaceuticals provides update on research and development programs
  • Sep 13, 2019: Mallinckrodt analysis suggests Acthar Gel may be a cost-effective option compared to other late-line, adult treatments for Multiple Sclerosis Relapse
  • Sep 09, 2019: Rhythm Pharmaceuticals to provide an update on genetic sequencing efforts and expansion of Phase 2 Basket study with four additional rare MC4R Pathway-driven Disorders
  • Aug 27, 2019: AMAG Pharmaceuticals announces commercial availability of Vyleesi (Bremelanotide Injection)
  • Aug 07, 2019: Rhythm Pharmaceuticals announces positive topline results from pivotal phase 3 clinical trials evaluating Setmelanotide in POMC and LEPR deficiency obesities
  • Aug 06, 2019: Palatin Technologies to present data on Vyleesi at Canaccord Genuity's 39th Annual Growth Conference
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Aequus BioPharma Inc, H2 2019
  • Pipeline by Eton Pharmaceuticals Inc, H2 2019
  • Pipeline by Palatin Technologies Inc, H2 2019
  • Pipeline by Rhythm Pharmaceuticals Inc, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top